## **Respiratory Research**



Correction Open Access

## Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review

Milo A Puhan\*, Daniela Vollenweider, Tsogyal Latshang, Johann Steurer and Claudia Steurer-Stey

Address: Horten Centre, University Hospital of Zurich, Postfach Nord, CH-8091 Zurich, Switzerland

Email: Milo A Puhan\* - milo.puhan@usz.ch; Daniela Vollenweider - danivollenweider@yahoo.de; Tsogyal Latshang - Tsogyal.Latshang@usz.ch; Johann Steurer - johann.steurer@usz.ch; Claudia Steurer-Stey - claudia.stey@usz.ch

Received: 2 July 2008 Accepted: 15 December 2008

\* Corresponding author

See related research article by Puhan et al., http://respiratory-research.com/content/8/1/30

Published: 15 December 2008

Respiratory Research 2008, 9:81 doi:10.1186/1465-9921-9-81

This article is available from: http://respiratory-research.com/content/9/1/81

© 2008 Puhan et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correction

Since publication of our article [1], we have been made aware of an error in our article.

We have transposed the proportion of patients with treatment failure in the antibiotic and placebo groups of one trial [2]. 19 out of 57 patients experienced a treatment failure compared to 28 out of 59 patients in the placebo group (odds ratio 0.55 (0.26–1.17).

In the results section of the abstract the sentences "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials ( $I^2 = 82\%$ ). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.016): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 1.09, 95% CI 0.75–1.59,  $I^2 = 18\%$ )" the text should read: "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials ( $I^2 = 75\%$ ). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.038): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 0.81, 95% CI 0.55–1.18,  $I^2 = 13\%$ )."

In the results section, following the subheading "Effects of antibiotics" the second paragraph "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials

( $I^2 = 82\%$ ). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.55), definition of outcomes (p = 0.20), length of follow-up (p = 0.38) and study quality (p = 0.92) did not explain heterogeneity." should read "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials ( $I^2 = 75\%$ ). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.59), definition of outcomes (p = 0.06), length of follow-up (p = 0.85) and study quality (p = 0.42) did not explain heterogeneity."

In the results section, following the subheading "Effects of antibiotics" the fourth paragraph "When we did the metaanalysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.016). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 1.09, 95% CI 0.75–1.59,  $I^2 = 18\%$ ). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.55, 95% CI 0.41-0.74, with a number-needed to treat of 9, 95% CI 6-16) but there was a large amount of heterogeneity ( $I^2 = 87\%$ )." should read "When we did the meta-analysis without this trial, we found that severity of exacerbations was associ-




Figure I
Forest plot showing ten studies that compared the effects of antibiotics and placebo on treatment failure. The x-axis represents the odds ratio for treatment failure. An odds ratio below I represents a lower chance of treatment failure with antibiotics. Studies not reporting treatment failures could not be included in the meta-analysis.

Study	Treatment failures (No of Events/Total No)		Odds ratio (95% CI) (Fixed-effects Models)	Favours antibiotics	4	Favours placebo	
	Antibiotics	Placebo					
Elmes 1957	4/42	4/41	0.97 (0.23-4.18)	_	+		
Berry 1960	0/26	5/27	0.08 (0.00-1.47)	_			
Anthonisen 1987	19/57	28/59	0.55 (0.26-1.17)				
Jorgensen 1992	49/132	49/136	1.05 (0.64-1.72)		<u> </u>		
Sachs 1995	4/40	2/21	1.06 (0.18-6.30)			_	
Overall (95% CI)	85/299	79/282	0.81 (0.55-1.18)		<b>\rightarrow</b>		
Test for heterogeneity	χ²=4.61, I²=13%	s, p=0.33					
Pines 1968	5/15	12/15	0.13 (0.02-0.66)				
Pines 1972	58/176	53/86	0.31 (0.18-0.52)				
Alonso Martinez 1992	4/61	6/29	0.27 (0.07-1.04)	_			
Nouira 2001	3/47	16/46	0.13 (0.03-0.48)				
Overall (95% CI)	70/299	87/176	0.25 (0.16-0.39)		$\Diamond$		
Test for heterogeneit	y χ²=2.22, I²=0%	%, p=0.53			T		
				0.01 0.1	1	10	
					Odds ratio (95% CI)		

Figure 2
Forest plot showing nine studies grouped according to severity of exacerbation. One study with a substantially higher treatment failure rate and a short follow-up of five days was not considered in the analysis. The upper five studies included patients with mild to moderate exacerbations and the four studies below included patients with severe exacerbations. The x-axis represents the odds ratio for treatment failure. An odds ratio below I represents a lower chance of treatment failure with antibiotics. Studies not reporting treatment failures could not be included in the meta-analysis.

ated significantly with treatment effects (p = 0.038). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 0.81, 95% CI 0.55–1.18,  $I^2 = 1$  three%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.45, 95% CI 0.34–0.61, with a number-needed to treat of 9, 95% CI 7–12) but there was a large amount of heterogeneity ( $I^2 = 83\%$ )."

The corrected versions of Figures two and three are given here- see figures 1 and 2.

We apologize for any inconvenience or confusion that this may have caused.

## References

- Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C: Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respiratory research 2007, 8:30.
- Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987, 106(2):196-204.

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- $\bullet$  peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- $\bullet$  yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing\_adv.asp

